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1. Introduction
  Fetal growth restriction (FGR) is one of the important 
subjects of modern obstetrics due to the close relation 
between birth weight and the morbidity and mortality 
rate of the perinatal infants. And because of complex 
mechanisms of FGR, high perinatal mortality and lack 
of effective treatment, FGR is well known as refractory 
disease in the field of fetal medicine. The present study 
aimed to study the expression change of soluble vascular 
endothelial growth factor receptor-1 (soluble VEGF receptor 
1, sFlt-1) and placental growth factor (PIGF) in the placentas 
and peripheral blood of FGR models of rats and pregnant 
women, to study the intervention effect of ligustrazine on 
the above mentioned indicators in fetal rats and pregnant 
women, and to explore the role and mechanisms of sFlt-1 
and PLGF in the pathogenesis of FGR, so as to provide some 
ideal methods for clinical treatment of FGR and possible 
monitoring indicators.
Objective: To investigate the expression of soluble vascular endothelial growth factor receptor-1 
(sFlt-1) and placental growth factor (PLGF) in the fetal growth restriction (FGR) cases and the 
intervention mechanism of tetramethylpyrazine. Methods: A total of 60 fetal growth restriction 
cases that admitted to our hospital were randomly divided into ligustrazine intervention group 
(group A) and nutritional support group (group B). A total of 50 healthy pregnant women were also 
enrolled as control group (group C). Expression level of maternal serum sFlt1, PLGF and fetal 
growth parameters including HC, AC, FL, BPD, EFW as well as placenta PLGF, sFlt-1 mRNA 
expression were recorded and compared among the three groups. A total of 15 SD rats were 
selected and were divided into three groups, TMP group, alcohol and tobacco group and blank 
control group. Three groups of rats were dissected on the twentieth day of gestation. Result: 
Expression level of sFlt-1 and PLGF in group A was not significantly different from that of group 
C (P＞0.05); but significant difference in SFlt1 and PLGF expression level was observed between 
group C and group B (P＜0.05). Before treatment, HC, AC, FL, BPD and EFW of group A and 
group B were significant lower than those of group C, but after treatment, those parameters in 
group A were significantly improved (P<0.05). In the animal experiment there was no significant 
difference in sFlt-1 between treatment group and FGR group without treatment or control group 
(P>0.05). There was significant difference in PLGF between FGR group with treatment and FGR 
group without treatment or control group (P<0.01). Conclusions: PLGF level is decreased and 
sFlt-1 increased in patients suffered from fetal growth restriction, and FGR rats show increased 
sFlt-1 and decreased PLGF, thus they can be indicator of the fetal growth restriction. Ligustrazine 
can effectively improve sFlt-1,PLGF expression level in fetal growth restriction cases, which can 
be used as treatment for FGR.
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2. Materials and methods
2.1. Animal experiments
  To investigate the expression changes of sFlt-1 and 
PLGF in the fetals of FGR rats and the treatment effect of 
tetramethylpyrazine (TMP) injection on FGR, 15 SD rats were 
used and randomly divided into TMP group (FGR treatment 
group), FGR non-treatment group and normal control 
group. The FGR treatment group was daily intragastrically 
administered with alcohol and exposed to tobacco smoking 
for three times (each time for 15 min). From the 13th day, 
after the treatment of alcohol and tobacco TMP were 
injected (ip.) at a dose of 8 mg/kg each day. Rats in the non-
treatment group, from the 7th day of pregnancy, were daily 
administered with alcohol and exposed to tobacco smoking 
three times (each time for 15 min). The normal control rats 
were administered with normal saline at a dose of 9 mL/kg
at 9 o’clock from the 7th day and kept in the smoking boxes 
without smoking for three times each day (each time for 
15 min). All the rats in the three groups were dissected on 
Day 20 and RT-PCR was used to detect and compare the 
expression of PLGF and sFlt-1 in the placentas of the rats 
among the three groups.
2.2. Clinical experiments
2.2.1. FGR diagnostic criteria
  Patients with the following conditions at the same time 
were included in the study: 1) with a clear gestational age 
and without endogenous FGR, like fetal malformation and 
chromosome abnormality; 2) fetal weights by ultrasound 
examination were estimated to below the average weight 
of gestational age or lower than the average weight by two 
standard deviations. Ultrasound diagnosis and monitoring 
were operated by designated persons. During the monitoring, 
ultrasonic Doppler examination of uterine artery and 
umbilical cord blood flow were done at the same time. 
2.2.2. Methods
  A total of 60 FGR cases that admitted to our hospital were 
selected and 50 healthy pregnant women were also enrolled 
as control group (group C). Urine and serum samples (2 mL) 
were collected from all the pregnant women and kept at  -80 ℃
in the refrigerator for further use. 
  The 60 FGR cases were randomly divided into two 
treatment groups, ie. ligustrazine intervention group (group 
A) and nutritional support group (group B) with 30 cases 
in each group. Group B were given low molecular weight 
dextran, vitamin C and intravenous drip of amino acid once 
a day for 7 days. For group A, in addition to the treatment 
for group B, patients were also given intravenous drip of 
ligustrazine (120 mg) once a day for 7 days. The urine and 
serum samples of all the patients were collected before and 
after the treatments.
  Follow-up visits were done after the birth of fetal to record 
their growth and developement parameters, including fetal 
head circumference (HC), abdomen circumference (AC), 
femur length (FL), fetal biparietal diameter (BPD), estimated 
fetal weight (EFW). Placenta specimens of the pregnant 
women were taken after childbirth. A sample of 1 cm伊1 cm伊
1 cm placenta tissue near the root of the umbilical cord were 
taken and kept at - 80 曟 in a refrigerator. The mRNA levels 
of sFlt-1 and PIGF were detected using RT-PCR method.
  Peripheral blood, sFlt-1 and PLGF of placenta and growth 
parameters of fetals by ultrasound were recorded. The results 
were analyzed and the differences of detected indicators 
were compared among all the groups.
3. Results
3.1. Expression of sFlt-1 and PLGF in the serum of FGR 
cases
  The PLGF levels in the experimental and control groups 
were (1 462.39依364.51) and (2 685.05依322.61) pg/mL, 
respectively. And the sFlt-1 levels of the two groups were (9 
509.67依1 406.91) and (4 103.42依661.82) pg/mL, respectively. 
The PLGF and sFlt-1 levels in both groups were statistically 
significant (P<0.05). The level of sFlt-1 was elevated and 
PLGF decreased in the serum of FGR pregnant women. 
Hence, sFlt-1 and PLGF can be considered as screening 
indicators of FGR.
3.2. Expression of sFlt-1 and PLGF in the placenta of FGR 
cases
  mRNA of PLGF and sFlt-1 was expressed in the placentas 
of both groups. The expression of PLGF in FGR group was 
significantly lower than that in the control group, with 20.57
依2.10 and 25.95依3.68, respectively (P<0.05). The expression 
of sFlt-1 mRNA in FGR group was significantly higher 
than that of control group with 32.36依3.13 and 27.25依3.34, 
respectively (P<0.05).
  The expression of PLGF mRNA in patients with FGR 
decreased in placental tissue, while sFlt-1 mRNA expression 
increased, which may have certain effect to the pathogenesis 
of FGR. 
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3.3. Effect of ligustrazine on fetal growth parameters
  After treatment, BPD, HC, AC, FL, EFW in group A 
increased significantly, which were statistically significant 
compared with those in group B (P<0.05). The resistance to 
umbilical cord blood flow and blood rheological parameters 
in Group A pregnant woman were significantly lower than 
that in group B (P<0. 05). The cure rate and total effective 
rate in group A was significantly higher (P<0.05) (Table 1).
3.4. Effect of ligustrazine intervention on the placental sFlt-1 
and PLGF
  Application of ligustrazine for the treatment of FGR can 
significantly improve the levels of sFlt -1 and PLGF in 
placenta, ameliorate blood rheological status of the FGR 
pregnant women, reduce the circulation resistance of uterine 
placenta, improve the placental villus microcirculation, 
promote in utero fetal growth and development and increase 
the neonatal birth weight.
3.5. Effect of ligustrazine intervention on the placental sFlt-1 
and PLGF
  The expression levels of sFlt-1 and PLGF in group A 
showed no significant difference compared with group C 
(P>0.05). Expression of sFlt-1 and PLGF in Group B was 
significant different from that of group C (P<0.05) (Table 2).
  So it can be concluded that the application of ligustrazine 
for the treatment of FGR can significantly recover sFlt-1 and 
PLGF levels in placentas, which is safe and cost-efficient.
3.6. sFlt - 1, PLGF expression in placentas of FGR rats and 
effect of ligustrazine intervention 
  Compared with the control group, the value of sFlt-1 in 
FGR non-treatment group significantly increased (P<0.01), 
while no significant difference was observed between FGR 
treatment group and FGR non treatment group (P>0.05).
  Compared with control group, the value of PLGF in FGR 
non treatment group decreased (P<0.01) and this value in 
decreased in FGR treatment group compared with FGR non 
treatment group (P<0.01) (Table 3).
  The level of sFlt-1 increased and PLGF decreased in the 
placentas of FGR rats, so these two parameters may be 
considered as the screening indicators of FGR. Treatment 
with ligustrazine did not change sFlt-1 in the placentas 
of rats significantly, although PLGF elevated. Hence, 
ligustrazine can be considered as treatment drug for FGR.
  It could be concluded from the present study that PLGF 
mRNA expression in placental tissue of patients with FGR 
reduced and sFlt-1 mRNA expression elevated. sFlt-1 in 
the pregnancy serum of FGR elevated and PLGF decreased. 
sFlt-1 increased and PLGF decreased in the placentas of 
FGR rats. After the treatment of ligustrazine, the sFlt-1 in 
the placentas of rats did not show any significant change but 
Table 1
 Growth and development parameters in the fetal of three groups (mean依sd).
Group No. of cases HC (cm)      AC (cm) FL (cm)  BPD (cm) EFW (kg)
Group A Before treatment 30  26.96依1.51*  25.02依2.15*  5.52依0.53*  7.51依0.62*   1.41依0.28*
After treatment  28.41依1.38#  27.06依2.66#    5.86依0.48#  7.86依0.55#   1.72依0.04#
Group B Before treatment 30  27.13依1.62*  25.01依2.41*  5.41依0.62*  7.50依0.46*    1.43依0.41*
After treatment  28.31依1.53#  26.32依2.82#  5.63依0.53#  7.67依0.58#    1.61依0.33#
Group C 50 28.43依1.82 27.11依2.53 5.88依0.63 7.92依0.52   1.71依0.31
*P＜0.05 compared with group C; #P＜0.05 compared with parameters before treatment within a group.
Table 2
Comparison of sFlt-1 and PLGF expression in the three groups (mean依sd).
Group    n sFlt-1      PLGF
A 30 28.17依3.0    24.89依3.15
B 30       32.36依3.135*#    20.57依2.1*#
C 50  27.25依3.34    25.95依3.68
*P＜0.05 compared with Group C; #P＜0.05 compared with Group A.
Table 3
Comparison of PLGF and sFlt-1 expression in placentas of rats in three groups. 
Group n PLGF sFlt-1
FGR treatment (A) 10  2.75依0.22# 1.39依0.35
FGR non-treatment(B) 10  0.28依0.07*  1.69依0.55*
Normal control (C) 10 1.36依1.37 1.13依0.09
*P<0.01 when compared with control group; #P<0.01 when compared with FGR non-treatment group.
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PLGF increased. The mutual antagonism between sFlt-1 and 
PLGF was likely to have certain effect on the pathogenesis of 
FGR, which was one of the most potential detection indexes 
in FGR study. Both animal experiments and clinical study 
have shown that application of ligustrazine treatment in 
FGR cases can siginificantly recover the sFlt-1 and PLGF 
levels. Ligustrazine can improve the rheological property of 
blood, decrease circulation resistance of placenta, improve 
the improve the placental villus microcirculation, promote 
in utero fetal growth and development and increase the 
neonatal birth weight.
4. Discussion
   The complicated mechanism of FGR leads to high 
perinatal mortality, and the lack of effective treatment 
makes it a refractory disease in the field of fetal medicine. 
The role of sFlt-1 and PIGF on the pathogenesis of FGR 
draws a lot of attention and is regarded as a new hot spot. 
PLGF is a kind of secretory dimers glycoprotein in the family 
of vascular endothelial growth factors. It can realize its 
biological effect by promoting the growth of blood vessels 
through binding with its receptors. The decrease of PLGF 
secretion from placenta trophocyte can cause angiogenesis 
obstacles in the placental villus. Transport of oxygen and 
nutrients would be blocked by underdeveloped placental 
vascular networks, resulting in the occurrence of FGR. 
The level of sFlt-1 expressed by placenta trophocyte may 
rise due to relatively anoxic environment induced during 
pregnancy. The combination of a large number of sFlt-1 and 
PLGF, VEGF can cause dysplastic placenta angiogenesis, 
leading to FGR. The mutual antagonism of sFlt-1 and PLGF 
makes it the most potential indicator in FGR study. The 
present study proved both in animal models and clinical 
tests, in mRNA and pregnancy serum that sFlt-1 increased 
and PLGF decreased in the placenta and blood of pregnant 
women when suffering from FGR. The mutual antagonism of 
sFlt-1 and PLGF has certain effect on the pathogenesis of 
FGR, which is one of the most potential detecting indicator 
in FGR study[1-4].
  Appropriate treatment during gestation period can reduce 
the perinatal mortality when diagnosed with FGR. The 
chemical structure of ligustrazine used in the present study 
is tetramethylpyrazine which is extracted from the rhizome 
of Chinese medicinal plant Ligusticum wallichii (family 
Apiaceae). Ligustrazine possesses typical characteristics 
as a calcium antagonist. It can regulate the function of 
platelet, reduce blood viscosity, improve blood rheological 
property, expand capillaries and recover microcirculation. 
It also possesses anticoagulant properties. Ligustrazine can 
help to inhibit the fibrosis of placental villi and human 
embryo cells, enhance the level of HPL and E3. It can also 
expand blood vessels without affecting blood pressure at 
small doses and down-regulate the blood pressure at large 
doses. The equilibrium of the pro-oxidant/antioxidant 
system in the body can also be adjusted by ligustrazine 
through enhancing the activity of superoxide dismutase 
and radical scavenging effect of superoxide dismutase, 
reducing damages from oxygen free radicals on placental 
villi, preventing placenta fibrosis, improving the function of 
the placenta and promoting fetal growth and development. 
After ligustrazine treatment, sFlt-1 and PLGF levels in 
placenta was significantly improved. Hence, ligustrazine can 
be considered as a therapy for FGR. The selected subjects 
are all singleton pregnancy and FGR related researches on 
gemellary pregnancy are now being carried out. Due to its 
remarkable therapy effects, convenient accessibility, low 
cost, safe and economical efficiency, ligustrazine has a good 
clinical application prospect[5-7]. 
  Both sFlt-1 and Flt 1 belong to vascular endothelial growth 
factor receptor (VEGFR). VEGFR competes with Flt 1 to 
combine with VEGF, completely inducing inactivation of 
VEGF, block of angiogenesis and affecting the permeability 
and integrity of vessel walls[8-12]. PLGF is one of the members 
of VEGF family. When PLGF combines with Flt 1 receptors, 
PLGF can promote the proliferation and infiltration of villi 
trophocyte. However, all these biology functions can be 
blocked by sFlt-1, as the strong antagonism effect of sFlt-1 
against PLGF can regulate the function of PLGF[13,14]. The 
role of sFlt-1 in the occurrence and development process 
of preeclampsia may be related to the signal transduction 
pathway of phosphate ester acyl inositol 3 kinase/protein 
kinase B (PI3K/Akt). Combined determination of PLGF 
and sFlt-1 in the blood of pregnant women can provide a 
relatively high sensitivity and specificity in predicting the 
occurrence of preeclampsia[15-18].
  With the development of research, it was found that the 
relationship of sFlt-1 and PLGF with the disease severity 
was linear, which was related to the non-synchronized 
development in twin pregnancy. At the same time, changes 
of sFlt-1 appeared earlier. When PLGF combines with Flt 
1 receptors, it can promote the generation of angiogenesis 
and the proliferation and infiltration of villi trophocyte. It 
was suggested in the present animal sudy that ligustrazine 
showed a more apparent effect on placenta than sFlt-1 did. 
Recently, PLGF has been tried to be used and studied as 
an indicator of clinical, including the design of the kits for 
rapid detection[19-22]. PLGF detection is simple and efficient 
and could be used as early as 11-14 weeks in pregnancy, 
which provide a efficient way for the early detection, early 
prevention and early diagnosis.
  In conclusion, sFlt-1 increased and PLGF decreased in 
FGR maternal serum and placenta, thus they can be used 
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as FGR detection indicators; ligustrazine therapy can 
significantly improve the blood rheological property and 
levels of PLGF and sFlt-1 in placenta in FGR pregnant 
women, thus ligustrazine can be used as an effective therapy 
for FGR with certain scientific significance and of favorable 
clinical application prospects.
 
Conflict of interest statement
  We declare that we have no conflict of interest.
Acknowledgements
  The authors would like to express their heartfelt thanks to 
Animal Center of Hainan Medical University, Mr. Guo-Hui 
Yi, Central Laboratory of Hainan Medical College, Dr. Zhi 
Zhou, Reproductive Center, Affiliated Hospital of Hainan 
Medical University and Mr. Huo Fu, Laboratory Department 
and Gynaecology And Obstetrics for their cooperation and 
supports.
References
[1]   Cui SH, Zhang LD. Study on placenta growth factor,Bcl-2 and 
FasL in fetal growth restriction. Maternal Child Health Care China 
2010; 25(24):3421-3423.
[2]   Tripathi R, Rath G, Ralhan  R, Saxena S, Salhan S. Soluble and 
membranous  vascular endothelial  growth factor receptor-21in 
pregnancies  complicated by pre-eclampsia. Yonsei Med J 2009; 
50(5): 656-666.
[3]   Zhou Q, Liu HY, Zeng WJ, Gong X, Wu YY, Qiao FY. Expression 
of soluble fms-like tyrosine kinase-1 under hypoxia in human 
first-trimester extravillous trophoblast cell line TEV-1 and 
human umbilical vein endothelial cell line EVC-304. Prog Obstet 
Gynecol 2009; 18(11): 36-38.
[4]   Rajakumar A, Powers RW, Hubel CA, Shibata E, von Versen-
Höynck F, Plymire D, et al. Novelsoluble Flt-1 isoforms in 
plasma and cultred placental explants from normoten sive 
pregnant and preeclamptic women. Placenta 2009; 30(1): 25-34.
[5]   Zhang ZE, Wang Y. The impaction of tetramethylpyrazine on 
hemorheology of pregnant woman with fetal growth restriction. 
China Med Herald 2012; 9(5): 51-53, 55.
[6]   Cheng CY, Sun Y, Wen ZB, He XF, Wang GF, Lin GQ, et al. 
Effects of tetramethylpyrazine on thrombin-induced tissue factor 
expression in vascular endothelial cells. J Southern Med Univ 
2009; 29(8): 1743-1748.
[7]   Yu N. Experimental study of the effect of ligustrazin liquid injection 
on rats with FGR-induced by smoking and drinking alcohol. 
Shanxi: Shan Xi Med Univ; 2006.
[8]   Al-Ani B, Hewett PW, Cudmore MJ, Fujisawa T, Saifeddine 
M, Williams H. Activation of proteinaseactivated receptor 2 
stimulates soluble vascular endothelial growth factor receptor 1 
release via epidermal growth factor receptor transactivation in 
endothelial cells. Hypertension 2010; 55(3): 689-697.
[9]   Ye LF, Ling Y, Zeng RR, Jin S. Impaction of tetramethylpyrazine 
on hemorheology of pregnant woman with fetal growth restriction. 
Maternal Child Health Care China 2013; 14(28): 2213-2215.
[10] Ranjit A, Argyro S, Leona P, David W, Kypros H. Competing risks 
model in early screening for preeclampsia by biophysical and 
biochemical markers Ranjit Akolekar. Fetal Diagn Ther 2013; 33: 
8-15.
[11] Qin J, Pan SH, Li XL, He LW, Jie D. Serum level of soluble Fms-
like tyrosine kinase-1(sFlt-1) and expression of membrane-bound 
Fms-like tyrosine kinase-1 of women with pre-eclampsia before 
and after magnesium sulfate therapy. China Pharmaceuticals 
2013; 22(12): 55-57.
[12] Zhang DX, Chen X.The relation between sFlt-1 and preeclampsia. 
Chin J Birth Health ＆ Heredity 2013; (5): 146-147.
[13] Liu W, Fu XD. sFlt-1 level in the serum of preeclampsia patients. 
J Luzhou Med College 2012; (2): 169-171.
[14] Xiong ZJ, Zhu CS, Liang L, Zheng ZD, Li Q. Inhibiting effect of 
sFlt-1 on migration of human monocytic THP-1 cells in response 
to VEGF. J Xinjiang Med Univ 2012; 35(7): 925-930.
[15] He SQ, Yan JY. sFlt-1, PLGF and their role in pathogensis and 
prediction of preeclampsia. J Int Obst Gynecol 2012; 39(3): 271-
275.
[16] He QJ, Cao YL, Zhu Q, Yang LF, Huo L. Clinical research of 
expression of VEGF and its receptor sFlt-1 in early and late onset 
of severe preeclampsia. Int Med Health Guidance News 2012; 
18(12): 1724-1726.
[17] Wang ML, Liang RC. The correlation study of nonidentity in body 
mass of dichorionic twin and VEGF and sFlt-1. J New Med 2012; 
(1): 42-45.
[18] Zhou J, Sun Y, Yang HX. Expression and significance of soluble 
fms-like tyrosine kinase-1 in preeclampsia placent. Chin J 
Perinatal Med 2012; 15(5): 291-293.
[19] Saffer C, Olson G, Boggess KA. NORMALS Study Group: 
Determination of placental growth factor (PlGF) levels in healthy 
pregnant women without signs or symptoms of preeclampsia. 
Pregnancy Hypertens 2013; 3: 124-132.
[20] Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA, et al. Can 
placental growth factor in maternal circulation identify fetuses 
with placental intrauterine growth restriction? Am J Obstet Gynecol 
2012; 206(163): e1-e7.
[21] Verlohren S, Herraiz I, Lapaire O, Holzgreve W, Galindo A, 
Engels T, et al. The sFlt-1/PlGF ratio in different types of 
hypertensive pregnancy disorders and its prognostic potential in 
preeclamptic patients. Am J Obstet Gynecol 2012; 206(58): e1-e8.
[22] Knudsen UB, Kronborg CS, von-Dadelszen P. A single rapid 
point of care placental growth factor determination as an aid in the 
diagnosis of preeclampsia. Pregnancy Hypertens 2012; 2: 8-15.
